Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 3034-31-9 | MDL No. : | MFCD00459246 |
Formula : | C12H10N2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FCTZHFATVFONMW-UHFFFAOYSA-N |
M.W : | 198.22 g/mol | Pubchem ID : | 220840 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 58.45 |
TPSA : | 41.99 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.41 cm/s |
Log Po/w (iLOGP) : | 1.66 |
Log Po/w (XLOGP3) : | 1.55 |
Log Po/w (WLOGP) : | 2.14 |
Log Po/w (MLOGP) : | 1.47 |
Log Po/w (SILICOS-IT) : | 2.07 |
Consensus Log Po/w : | 1.78 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.44 |
Solubility : | 0.721 mg/ml ; 0.00364 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.04 |
Solubility : | 1.8 mg/ml ; 0.00909 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.55 |
Solubility : | 0.00564 mg/ml ; 0.0000284 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.3 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
99% | Stage #1: for 2 h; Reflux Stage #2: With potassium carbonate In tetrahydrofuran at 20℃; for 24 h; |
A solution of isonicotinic acid (14, 5.0 g, 40.6 mmol) in thionyl chloride (40 mL) was heated at reflux for 2 h. After completion of the reaction, thionyl chloride was removed under reduced pressure. THF (50 mL), K2CO3 (16.8 g, 121.9 mmol) and aniline (3.78 g, 40.6 mmol) were added to the residue and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was concentrated and the residue was recrystallized from EtOAc-hexanes (60:40) to afford the product 15 (8.0 g, 99percent) as a light yellow solid: mp 166-168 °C. IR (KBr) 1344, 1653, 1465, 665 cm 1; *H NMR (DMSO-ifc, 300 MHz) δ 10.49 (s, 1 H), 8.78 (m, 2 H), 7.86 (m, 2 H), 7.78 (m, 2 H), 7.39 (t, = 8.0 Hz, 2 H), 7.15 (t, = 6.5 Hz, 1 H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
89% | Stage #1: With 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 40℃; for 2.5 h; Stage #2: for 20 h; |
A solution of 1,10-carbonyldiimidazole (130 g,0.81 mol), isonicotinic acid (100 g, 0.81 mol) and DMF (300 mL) was heated at 40 C for 2.5 h before aniline (100 g, 0.81 mol) was added in a single portion. After 20 h, water (1.2 L) was added. The resulting suspension was filtered andthe solids dried under vacuum to afford isonicotinanilide (39) (142.6 g, 89percent). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
73% | With potassium <i>tert</i>-butylate; copper(ll) bromide In <i>tert</i>-butyl alcohol at 20℃; for 37 h; | General procedure: A 10 mL round-bottomed flask was charged with the appropriate nitrile 2 (0.50 mmol), arylboronic acid 1(0.60 mmol), CuBr2 (6 mg, 5molpercent), t-BuOK (168 mg, 1.50 mmol), and t-BuOH (3.0 mL), and the mixture was stirred at r.t. until the reaction was complete (TLC). H2O (4.0 mL) was added, and the mixture was extracted with EtOAc (3 ×10 mL). The combined organic layers were washed twice with H2O,dried (Na2SO4), and concentrated to give a residue that was purified by column chromatography (silica gel, PE–EtOAc). |
[ 76102-92-6 ]
2-Amino-N-(pyridin-3-yl)benzamide
Similarity: 0.89
[ 80194-83-8 ]
2-Chloro-N-phenylisonicotinamide
Similarity: 0.84
[ 74441-06-8 ]
4-Amino-N-(4-carbamoylphenyl)benzamide
Similarity: 0.81
[ 91025-05-7 ]
N-(2-Picolinoylphenyl)benzamide
Similarity: 0.77
[ 76102-92-6 ]
2-Amino-N-(pyridin-3-yl)benzamide
Similarity: 0.89
[ 80194-83-8 ]
2-Chloro-N-phenylisonicotinamide
Similarity: 0.84
[ 80047-24-1 ]
2-Methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carboxamide
Similarity: 0.84
[ 29876-14-0 ]
N-(2-(1H-Indol-3-yl)ethyl)nicotinamide
Similarity: 0.82
[ 76102-92-6 ]
2-Amino-N-(pyridin-3-yl)benzamide
Similarity: 0.89
[ 80194-83-8 ]
2-Chloro-N-phenylisonicotinamide
Similarity: 0.84
[ 80047-24-1 ]
2-Methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carboxamide
Similarity: 0.84
[ 29876-14-0 ]
N-(2-(1H-Indol-3-yl)ethyl)nicotinamide
Similarity: 0.82
[ 74441-06-8 ]
4-Amino-N-(4-carbamoylphenyl)benzamide
Similarity: 0.81
[ 76102-92-6 ]
2-Amino-N-(pyridin-3-yl)benzamide
Similarity: 0.89
[ 80194-83-8 ]
2-Chloro-N-phenylisonicotinamide
Similarity: 0.84
[ 80047-24-1 ]
2-Methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carboxamide
Similarity: 0.84
[ 29876-14-0 ]
N-(2-(1H-Indol-3-yl)ethyl)nicotinamide
Similarity: 0.82